Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$13.69 USD
+0.11 (0.81%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $13.66 -0.03 (-0.22%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SAGE 13.69 +0.11(0.81%)
Will SAGE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SAGE
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
What's in Store for Biogen (BIIB) This Earnings Season?
Biotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study Success
Other News for SAGE
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
Sage Therapeutics price target lowered by $3 at H.C. Wainwright, here's why
Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment
Sage Therapeutics price target lowered by $11 at RBC Capital, here's why
Sage Therapeutics price target lowered by $4 at Canaccord, here's why